• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二氧化硅纳米颗粒的表面功能化:优化载体平台免疫激活特性的策略

Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms.

作者信息

Punz Benjamin, Johnson Litty, Geppert Mark, Dang Hieu-Hoa, Horejs-Hoeck Jutta, Duschl Albert, Himly Martin

机构信息

Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.

出版信息

Pharmaceutics. 2022 May 21;14(5):1103. doi: 10.3390/pharmaceutics14051103.

DOI:10.3390/pharmaceutics14051103
PMID:35631689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9146724/
Abstract

Silica nanoparticles (SiNPs) are generally regarded as safe and may represent an attractive carrier platform for nanomedical applications when loaded with biopharmaceuticals. Surface functionalization by different chemistries may help to optimize protein loading and may further impact uptake into the targeted tissues or cells, however, it may also alter the immunologic profile of the carrier system. In order to circumvent side effects, novel carrier candidates need to be tested thoroughly, early in their development stage within the pharmaceutical innovation pipeline, for their potential to activate or modify the immune response. Previous studies have identified surface functionalization by different chemistries as providing a plethora of modifications for optimizing efficacy of biopharmaceutical (nano)carrier platforms while maintaining an acceptable safety profile. In this study, we synthesized SiNPs and chemically functionalized them to obtain different surface characteristics to allow their application as a carrier system for allergen-specific immunotherapy. In the present study, crude natural allergen extracts are used in combination with alum instead of well-defined active pharmaceutical ingredients (APIs), such as recombinant allergen, loaded onto (nano)carrier systems with immunologically inert and stable properties in suspension. This study was motivated by the hypothesis that comparing different charge states could allow tailoring of the binding capacity of the particulate carrier system, and hence the optimization of biopharmaceutical uptake while maintaining an acceptable safety profile, which was investigated by determining the maturation of human antigen-presenting cells (APCs). The functionalized nanoparticles were characterized for primary and hydrodynamic size, polydispersity index, zeta potential, endotoxin contamination. As potential candidates for allergen-specific immunotherapy, the differently functionalized SiNPs were non-covalently coupled with a highly purified, endotoxin-free recombinant preparation of the major birch pollen allergen Bet v 1 that functioned for further immunological testing. Binding efficiencies of allergen to SiNPs was controlled to determine uptake of API. For efficacy and safety assessment, we employed human monocyte-derived dendritic cells as model for APCs to detect possible differences in the particles' APC maturation potential. Functionalization of SiNP did not affect the viability of APCs, however, the amount of API physisorbed onto the nanocarrier system, which induced enhanced uptake, mainly by macropinocytosis. We found slight differences in the maturation state of APCs for the differently functionalized SiNP-API conjugates qualifying surface functionalization as an effective instrument for optimizing the immune response towards SiNPs. This study further suggests that surface-functionalized SiNPs could be a suitable, immunologically inert vehicle for the efficient delivery of biopharmaceutical products, as evidenced here for allergen-specific immunotherapy.

摘要

二氧化硅纳米颗粒(SiNPs)通常被认为是安全的,当负载生物药物时,可能代表一种有吸引力的纳米医学应用载体平台。通过不同化学方法进行表面功能化可能有助于优化蛋白质负载,并可能进一步影响其被靶向组织或细胞的摄取,然而,这也可能改变载体系统的免疫特性。为了规避副作用,新型载体候选物需要在药物创新流程的早期开发阶段就针对其激活或改变免疫反应的潜力进行全面测试。先前的研究已经确定,通过不同化学方法进行表面功能化可以提供大量修饰,以优化生物药物(纳米)载体平台的功效,同时保持可接受的安全性。在本研究中,我们合成了SiNPs并对其进行化学功能化,以获得不同的表面特性,使其能够作为变应原特异性免疫疗法的载体系统。在本研究中,粗制天然变应原提取物与明矾联合使用,而不是定义明确的活性药物成分(APIs),如重组变应原,负载到具有免疫惰性和悬浮稳定性的(纳米)载体系统上。本研究的动机是这样一个假设,即比较不同的电荷状态可以调整颗粒载体系统的结合能力,从而在保持可接受的安全性的同时优化生物药物的摄取,这通过测定人抗原呈递细胞(APCs)的成熟情况来进行研究。对功能化纳米颗粒的初级粒径、流体动力学粒径、多分散指数、zeta电位、内毒素污染进行了表征。作为变应原特异性免疫疗法的潜在候选物,不同功能化的SiNPs与主要桦树花粉变应原Bet v 1的高度纯化、无内毒素的重组制剂非共价偶联,用于进一步的免疫学测试。控制变应原与SiNPs的结合效率以确定活性药物成分的摄取情况。为了进行功效和安全性评估,我们使用人单核细胞衍生的树突状细胞作为APCs的模型,以检测颗粒的APCs成熟潜力的可能差异。SiNP的功能化不影响APCs的活力,然而,物理吸附在纳米载体系统上的活性药物成分的量,主要通过巨胞饮作用诱导摄取增加。我们发现不同功能化的SiNP-活性药物成分缀合物在APCs成熟状态上存在细微差异,这证明表面功能化是优化针对SiNPs免疫反应的有效手段。本研究进一步表明,表面功能化的SiNPs可能是一种合适的、免疫惰性的载体,用于高效递送生物药物产品,本研究中变应原特异性免疫疗法就是例证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/783bb0f198e9/pharmaceutics-14-01103-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/938b40e30b69/pharmaceutics-14-01103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/9701796aee65/pharmaceutics-14-01103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/73cfb57de948/pharmaceutics-14-01103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/bc8a76c98d1a/pharmaceutics-14-01103-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/486afa3f6eba/pharmaceutics-14-01103-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/f905063162ad/pharmaceutics-14-01103-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/783bb0f198e9/pharmaceutics-14-01103-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/938b40e30b69/pharmaceutics-14-01103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/9701796aee65/pharmaceutics-14-01103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/73cfb57de948/pharmaceutics-14-01103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/bc8a76c98d1a/pharmaceutics-14-01103-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/486afa3f6eba/pharmaceutics-14-01103-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/f905063162ad/pharmaceutics-14-01103-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/783bb0f198e9/pharmaceutics-14-01103-g007.jpg

相似文献

1
Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms.二氧化硅纳米颗粒的表面功能化:优化载体平台免疫激活特性的策略
Pharmaceutics. 2022 May 21;14(5):1103. doi: 10.3390/pharmaceutics14051103.
2
Erratum: Preparation of Poly(pentafluorophenyl acrylate) Functionalized SiO2 Beads for Protein Purification.勘误:用于蛋白质纯化的聚(丙烯酸五氟苯酯)功能化二氧化硅微珠的制备
J Vis Exp. 2019 Apr 30(146). doi: 10.3791/6328.
3
A Quantitative Method for Determining Uptake of Silica Nanoparticles in Macrophages by Single Particle Inductively Coupled Plasma-Mass Spectrometry.一种通过单颗粒电感耦合等离子体质谱法测定巨噬细胞中二氧化硅纳米颗粒摄取量的定量方法。
Curr Protoc. 2022 Mar;2(3):e396. doi: 10.1002/cpz1.396.
4
Functionalized silica nanoparticles: a platform for fluorescence imaging at the cell and small animal levels.功能化硅纳米颗粒:用于细胞和小动物水平荧光成像的平台。
Acc Chem Res. 2013 Jul 16;46(7):1367-76. doi: 10.1021/ar3001525. Epub 2013 Mar 14.
5
Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice.介孔二氧化硅纳米颗粒作为免疫激活药物瑞喹莫德的pH响应载体可增强小鼠局部免疫反应。
ACS Nano. 2021 Mar 23;15(3):4450-4466. doi: 10.1021/acsnano.0c08384. Epub 2021 Mar 1.
6
Chitosan-coated ultrapure silicon nanoparticles produced by laser ablation: biomedical potential in nano-oncology as a tumor-targeting nanosystem.激光烧蚀制备的壳聚糖包覆超纯硅纳米颗粒:作为肿瘤靶向纳米系统在纳米肿瘤学中的生物医学潜力。
Nanoscale Adv. 2023 May 1;5(11):3044-3052. doi: 10.1039/d3na00253e. eCollection 2023 May 30.
7
The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals.主要桦树花粉过敏原 Bet v 1 可诱导桦树花粉过敏和健康个体树突状细胞产生不同的反应。
PLoS One. 2015 Jan 30;10(1):e0117904. doi: 10.1371/journal.pone.0117904. eCollection 2015.
8
Modification of the zeta potential of montmorillonite to achieve high active pharmaceutical ingredient nanoparticle loading and stabilization with optimum dissolution properties.通过改变蒙脱石的动电位实现高载药量和稳定性的药物活性成分纳米颗粒,并具有最佳的溶解性能。
Colloids Surf B Biointerfaces. 2020 Sep;193:111120. doi: 10.1016/j.colsurfb.2020.111120. Epub 2020 May 12.
9
Interactions at the silica-peptide interface: the influence of particle size and surface functionality.硅石-肽界面相互作用:颗粒大小和表面官能团的影响。
Langmuir. 2014 Jan 14;30(1):227-33. doi: 10.1021/la403242f. Epub 2013 Dec 20.
10
Human Hepatocarcinoma Cell Targeting by Glypican-3 Ligand Peptide Functionalized Silica Nanoparticles: Implications for Ultrasound Molecular Imaging.载有人肝癌细胞靶向肽的 Glypican-3 配体功能化硅纳米粒子:对超声分子成像的影响。
Langmuir. 2017 May 9;33(18):4490-4499. doi: 10.1021/acs.langmuir.7b00327. Epub 2017 Apr 27.

引用本文的文献

1
Instance maps as an organising concept for complex experimental workflows as demonstrated for (nano)material safety research.实例图作为复杂实验工作流程的组织概念,如(纳米)材料安全研究所示。
Beilstein J Nanotechnol. 2025 Jan 22;16:57-77. doi: 10.3762/bjnano.16.7. eCollection 2025.
2
Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance.用于诱导免疫耐受的树突状细胞靶向纳米递送系统的研究进展
Front Bioeng Biotechnol. 2023 Oct 9;11:1242126. doi: 10.3389/fbioe.2023.1242126. eCollection 2023.
3
Application of Nanomedicine in Immunotherapy: Recent Advances and Prospects.

本文引用的文献

1
Influence of serum concentration and surface functionalization on the protein adsorption to mesoporous silica nanoparticles.血清浓度和表面功能化对蛋白质吸附到介孔二氧化硅纳米颗粒上的影响。
RSC Adv. 2019 Oct 22;9(58):33912-33921. doi: 10.1039/c9ra05585a. eCollection 2019 Oct 18.
2
Nanoparticles for generating antigen-specific T cells for immunotherapy.用于免疫治疗中产生抗原特异性T细胞的纳米颗粒。
Semin Immunol. 2021 Aug;56:101541. doi: 10.1016/j.smim.2021.101541. Epub 2021 Dec 23.
3
Structural Alterations of Antigens at the Material Interface: An Early Decision Toolbox Facilitating Safe-by-Design Nanovaccine Development.
纳米医学在免疫治疗中的应用:最新进展与展望
Pharmaceutics. 2023 Jul 9;15(7):1910. doi: 10.3390/pharmaceutics15071910.
4
Mechanistic insights into silica nanoparticle-allergen interactions on antigen presenting cell function in the context of allergic reactions.在过敏反应的背景下,关于硅纳米颗粒-过敏原相互作用对抗原呈递细胞功能的机制见解。
Nanoscale. 2023 Feb 2;15(5):2262-2275. doi: 10.1039/d2nr05181h.
材料界面处抗原的结构改变:促进安全设计纳米疫苗开发的早期决策工具箱。
Int J Mol Sci. 2021 Oct 8;22(19):10895. doi: 10.3390/ijms221910895.
4
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals.抗聚乙二醇抗体:性质、形成、检测以及在聚乙二醇化纳米生物制药的不良反应中的作用。
Adv Drug Deliv Rev. 2020;154-155:163-175. doi: 10.1016/j.addr.2020.07.024. Epub 2020 Aug 1.
5
Amino-Functionalized Mesoporous Silica Nanoparticle-Encapsulated Octahedral Organoruthenium Complex as an Efficient Platform for Combatting Cancer.氨基功能化介孔二氧化硅纳米颗粒包裹的八面体有机钌配合物作为对抗癌症的高效平台
Inorg Chem. 2020 Jul 20;59(14):10275-10284. doi: 10.1021/acs.inorgchem.0c01436. Epub 2020 Jul 6.
6
Nanotechnology-Based Vaccines for Allergen-Specific Immunotherapy: Potentials and Challenges of Conventional and Novel Adjuvants under Research.基于纳米技术的变应原特异性免疫疗法疫苗:研究中传统佐剂和新型佐剂的潜力与挑战
Vaccines (Basel). 2020 May 20;8(2):237. doi: 10.3390/vaccines8020237.
7
Understanding the contribution of surface roughness and hydrophobic modification of silica nanoparticles to enhanced therapeutic protein delivery.了解二氧化硅纳米颗粒的表面粗糙度和疏水改性对增强治疗性蛋白质递送的作用。
J Mater Chem B. 2016 Jan 14;4(2):212-219. doi: 10.1039/c5tb01911g. Epub 2015 Dec 11.
8
When Would Immunologists Consider a Nanomaterial to be Safe? Recommendations for Planning Studies on Nanosafety.免疫学家何时会认为纳米材料是安全的?纳米安全规划研究建议。
Small. 2020 May;16(21):e1907483. doi: 10.1002/smll.201907483. Epub 2020 Apr 2.
9
The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.2019 年的制药行业。从分子角度分析 FDA 药物批准情况。
Molecules. 2020 Feb 9;25(3):745. doi: 10.3390/molecules25030745.
10
Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review.聚乙二醇化胶束载体系统的毒性和免疫原性问题:综述
Sci Technol Adv Mater. 2019 Apr 15;20(1):324-336. doi: 10.1080/14686996.2019.1590126. eCollection 2019.